| 2024-04-18 | -0.59 % |
- The article discusses Abbott Laboratories (ABT) stock, which despite strong first-quarter performance and raised guidance, experienced a decline of -0.59% due to broader market conditions and potential concerns over Nutrition litigation, with operating margins decreasing partly due to a decline in COVID-19 sales compared to the previous year.
- The article discusses Abbott Laboratories (ABT) stock, which was down by -0.59% last night, and provides financial metrics such as revenue, net income, profit margin, and EPS for the trailing 12-month period. The stock likely went down due to the decrease in profit margin driven by higher expenses and the net income being lower than in the previous quarter.
- Summary: The article discusses the global anti-hypertensive drug market, projecting significant growth due to increasing cases of hypertension globally, with Abbott Laboratories being one of the major vendors in this market.
Reason for Abbott Laboratories (ABT) stock going down: The stock of Abbott Laboratories might have gone down due to general market conditions, investor sentiment, or specific company-related news that could have impacted investor confidence in their performance or future growth prospects.
|
| 2024-04-17 | -3.03 % |
|
| 2024-04-16 | +0.29 % |
|
| 2024-04-11 | +0.25 % |
|
| 2024-04-10 | -1.13 % |
|
| 2024-04-09 | +1.74 % |
- The article discusses how Moseley Investment Management Inc. and other large institutional investors have recently increased their stakes in Abbott Laboratories (ABT) stock, with the stock being up 1.74% last night; the stock price increase is likely due to these significant investments from institutional investors like Morgan Stanley, Wellington Management Group LLP, Moneta Group Investment Advisors LLC, Northern Trust Corp, and Norges Bank, among others, and positive analyst ratings and price target increases.
- The article discusses Abbott Laboratories (NYSE:ABT) stock, which was up by 1.74% last night, with Bleakley Financial Group LLC increasing its position in the company by 1.4% in the 4th quarter, resulting in positive investor sentiment and subsequent stock price increase.
- The article discusses how Meeder Asset Management Inc. recently bought a new stake in Abbott Laboratories, impacting the stock positively with a 1.74% increase, as other institutional investors and hedge funds also acquired positions, attributing to its growth.
|
| 2024-04-08 | -0.61 % |
|
| 2024-04-05 | +0.99 % |
- Summary: Abbott Laboratories' stock (ABT) was up 0.99% last night, with institutional investors like Carmichael Hill & Associates Inc. reducing their stake while others like Moneta Group Investment Advisors LLC, Norges Bank, and Morgan Stanley increased their holdings, leading to a boost in the stock. This increase might be due to positive quarterly earnings results, corporate actions such as dividend payouts, and strong ratings from research firms.
Reason for stock increase: The stock of Abbott Laboratories (ABT) might have gone up due to positive quarterly earnings results, corporate actions like dividend payouts, and increased investor confidence based on strong ratings and recommendations from research firms.
- The article discusses how First Bancorp Inc ME lowered its stake in Abbott Laboratories stock by 34.7% during the fourth quarter, and various other institutional investors either added to or reduced their stakes in the company. The stock price of Abbott Laboratories went up by 0.99% the previous night, and the increase could be attributed to positive reports and ratings from several equities analysts, including a consensus price target of $122.14, as well as strong quarterly earnings data indicating earnings per share of $1.19 and revenue growth. Additionally, company insiders have been selling shares, and Abbott Laboratories recently announced a quarterly dividend.
- The article discusses how Farmers & Merchants Trust Co of Chambersburg PA increased its position in Abbott Laboratories stock by 5.1%, which led to the stock being up by 0.99%; the stock could be going up due to increased stake by various hedge funds and positive quarterly earnings results with a dividend announcement.
|
| 2024-04-02 | -0.06 % |
|
| 2024-04-01 | -1.38 % |
- The article discusses how institutional investors and hedge funds, including AdvisorNet Financial Inc and Moneta Group Investment Advisors LLC, have been increasing their holdings in Abbott Laboratories (ABT) stock, which saw a 1.38% decrease last night. The stock went down due to the increase in selling pressure by institutional investors and insider selling, with EVP Andrea F. Wainer selling a considerable number of shares, despite favourable quarterly earnings data and positive analyst ratings.
- The article discusses the recent -1.38% decrease in Abbott Laboratories (ABT) stock and provides information about Elanco Animal Health Incorporated appointing two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors, expounding on their experience in the animal health industry. The stock price of Abbott Laboratories may have gone down due to factors not directly related to this specific event, such as broader market conditions, company performance, or sector-specific news.
- The article discusses a recent development in a legal dispute surrounding the economic substance doctrine, which could impact transfer pricing decisions, and this shift has led to concerns and predictions that the economic substance doctrine will play a more significant role in future transfer pricing disputes; the stock price of Abbott Laboratories (ABT) went down by -1.38% as per last night’s data, but this decrease can't be directly attributed to the legal developments highlighted in the article.
|
| 2024-03-28 | +0.16 % |
|
| 2024-03-27 | +1.78 % |
|
| 2024-03-26 | +1.35 % |
|
| 2024-03-25 | -0.51 % |
|
| 2024-03-22 | -0.84 % |
|
| 2024-03-21 | +0.01 % |
- Hall Laurie J Trustee increased its holdings in Abbott Laboratories (NYSE:ABT) by 1.6%, with other institutional investors and hedge funds also making changes, causing ABT stock to go up last night; this increase could be due to positive investor sentiment and confidence in the company's performance and future prospects.
- The article discusses the healthcare sector's challenges and opportunities for growth in 2023 and 2024, highlighting advancements in pharmaceuticals, medical devices, and biotechnology. The stock of Abbott Laboratories (ABT) went up by 0.01% last night. Stocks like Johnson & Johnson (JNJ) saw growth due to strong financial performance and innovations in the healthcare industry, with increasing interest from strategic buyers and investors. The article also mentions the best healthcare ETFs to buy based on performance and holdings, focusing on companies like Eli Lilly and Company (LLY) and Natera, Inc. (NTRA). The healthcare sector's future is marked by changes driven by technology adoption, cost control strategies, and addressing health disparities.
- Abbott Laboratories (ABT) stock was up 0.01% last night as Jim Cramer's Charitable Trust decided to buy more shares amidst recent weakness, caused by market overestimation of risk related to pending lawsuits on infant formula litigation, with analysts suggesting potential settlements to be significantly less than market cap losses, presenting a buying opportunity due to overreaction.
|
| 2024-03-20 | -1.47 % |
|
| 2024-03-19 | +0.64 % |
|
| 2024-03-18 | -2.64 % |
|
| 2024-03-15 | -2.83 % |
|
| 2024-03-14 | -1.09 % |
|
| 2024-03-13 | -0.5 % |
|
| 2024-03-06 | +0.73 % |
|
| 2024-02-29 | -1.17 % |
|
| 2024-02-28 | +0.54 % |
- The article discusses the biotech industry and the potential benefits and risks associated with investing in biotech stocks, highlighting companies like Abbott Laboratories (ABT) and others such as Eli Lilly, Novo Nordisk, UnitedHealth Group, Johnson & Johnson, Merck, AbbVie, Thermo Fisher Scientific Inc., Roche Holding, and Novartis, explaining their market caps, key products, and recent financial performances. The reason for the increase in Abbott Laboratories (ABT) stock last night could be attributed to positive market sentiment, regulatory approvals, partnerships with larger pharmaceutical companies, or successful revenue generation from key products like Humira and Skyrizi.
|
| 2024-02-27 | +0.6 % |
|
| 2024-02-26 | -0.64 % |
- Summary: The article discusses a comparison between two small-cap medical companies, Tandem Diabetes Care and enVVeno Medical, based on various factors such as earnings, valuation, risk, institutional ownership, profitability, analyst recommendations, and dividends, where Tandem Diabetes Care is favored over enVVeno Medical due to its higher potential upside and institutional ownership.
Abbott Laboratories(ABT) stock went down mainly due to factors specific to the company, such as earnings reports, market conditions, investor sentiment, or specific news related to the company itself.
- Epoch Investment Partners Inc. lowered stake in Abbott Laboratories, causing the stock to go down by -0.64%; the stock drop may be attributed to large investors, like Patriot Investment Management Group and Camden National Bank, making changes to their positions in the company, alongside an executive selling a significant number of shares, despite good earnings and analyst ratings.
|
| 2024-02-23 | +0.37 % |
|
| 2024-02-22 | +0.98 % |
|
| 2024-02-21 | +1.05 % |
|
| 2024-02-20 | +2.31 % |
- The article discusses the importance of sustainability in the corporate sector, with a focus on the United States and companies like Abbott Laboratories (ABT) showcasing commitment to sustainability by focusing on innovation and social responsibility, leading to a positive impact on stock performance. Abbott Laboratories (ABT) stock went up due to its commitment to reducing GHG emissions, waste production, and supporting diverse businesses by providing grants, along with significant investments in research and development, aligning with sustainable development goals.
- The article discusses AbbVie's announcement of Robert Michael succeeding Richard Gonzalez as chief executive, effective July 1, following Gonzalez's tenure since 2013 when the company was formed after spinning off from Abbott Laboratories. The stock of Abbott Laboratories (ABT) went up by 2.31% last night, potentially due to positive market sentiments regarding the management transition at AbbVie, which was previously part of Abbott Laboratories.
|
| 2024-02-16 | +0.33 % |
|
| 2024-02-15 | +1.41 % |
|
| 2024-02-08 | -0.78 % |
|
| 2024-02-07 | -0.61 % |
|
| 2024-02-06 | +2.1 % |
|
| 2024-02-02 | -2.08 % |
|
| 2024-02-01 | +1.18 % |
|
| 2024-01-31 | -0.29 % |
|
| 2024-01-29 | +1.29 % |
|
| 2024-01-26 | -0.39 % |
|
| 2024-01-25 | +1.52 % |
|
| 2024-01-24 | -2.83 % |
|
| 2024-01-23 | -0.17 % |
|
| 2024-01-22 | -0.44 % |
|
| 2024-01-18 | +0.08 % |
|
| 2024-01-10 | +1.48 % |
|
| 2024-01-08 | +1.44 % |
|
| 2024-01-04 | +1.33 % |
|
| 2024-01-03 | -0.3 % |
|
| 2023-12-29 | -0.3 % |
|
| 2023-12-28 | +0.56 % |
|
| 2023-12-21 | +1.01 % |
|
| 2023-12-18 | +0.72 % |
- The article is not about Abbott Laboratories (ABT) stock, but rather about BioSig Technologies, Inc. The article does not mention why Abbott Laboratories stock goes up.
- Abbott Laboratories (ABT) stock went up by 0.72% after the company announced that its chairman and CEO will present at the J.P. Morgan Healthcare Conference, showcasing its portfolio of life-changing technologies in diagnostics, medical devices, nutritionals, and branded generic medicines.
- Abbott Laboratories (ABT) stock went up by 0.72% due to the approval of a dividend payment of USD 0.55 per share, to be paid on February 21, 2024, to entitled shareholders on January 10, 2024.
|
| 2023-12-15 | -1.21 % |
|
| 2023-12-14 | +1.26 % |
|
| 2023-12-13 | +0.53 % |
|
| 2023-12-08 | +0.44 % |
|
| 2023-12-07 | -0.85 % |
|
| 2023-12-06 | +0.57 % |
|
| 2023-12-05 | -0.8 % |
|
| 2023-12-04 | +0.3 % |
|
| 2023-12-01 | +0.57 % |
|
| 2023-11-30 | +0.64 % |
|
| 2023-11-29 | +1.54 % |
|
| 2023-11-28 | -0.63 % |
|
| 2023-11-22 | +0.78 % |
|
| 2023-11-21 | +0.7 % |
|
| 2023-11-20 | +1.66 % |
|
| 2023-11-17 | -0.71 % |
|
| 2023-11-16 | +2.31 % |
|
| 2023-11-15 | +0.95 % |
|
| 2023-11-14 | +1.35 % |
|
| 2023-11-13 | +1.94 % |
|
| 2023-11-09 | -1.26 % |
|
| 2023-11-08 | -0.06 % |
|
| 2023-11-07 | -0.21 % |
|
| 2023-11-06 | -0.88 % |
|
| 2023-11-03 | -0.13 % |
|
| 2023-11-02 | +1 % |
|
| 2023-10-31 | +1.67 % |
|
| 2023-10-27 | -1.2 % |
|
| 2023-10-26 | +0.44 % |
|
| 2023-10-25 | -1.31 % |
|
| 2023-10-24 | -1.01 % |
|
| 2023-10-19 | -0.13 % |
|
